ticagrelor + apixaban + acetylsalicylic acid

This is a combination therapy consisting of three agents: - **Ticagrelor** (a reversible P2Y12 receptor antagonist antiplatelet agent), - **Apixaban** (an oral direct factor Xa inhibitor anticoagulant), - **Acetylsalicylic acid** (aspirin, an irreversible cyclooxygenase inhibitor antiplatelet agent). The combination is used as triple antithrombotic therapy in patients with conditions such as atrial fibrillation and concurrent coronary artery disease, especially after percutaneous coronary intervention. The regimen aims to reduce the risk of thrombotic events by inhibiting platelet activation/aggregation and coagulation pathways. However, this triple therapy significantly increases the risk of major bleeding events compared to dual or monotherapy[1][2][3]. Clinical guidelines recommend careful patient selection and duration minimization due to bleeding risks.